Efficacy of Sulfadoxine-Pyrimethamine for Treating Malaria in Gabonese Children
Status:
Terminated
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
IPTi, a strategy whereby infants are provided treatment doses of antimalarials at routine
vaccination visits, has been shown to significantly reduce malaria and anemia in two studies
in Tanzania. However the results obtained in Gabon are not similar. Many factors are likely
to influence the efficacy or effectiveness IPTi. It is reasonable to assume that the efficacy
of IPTi will be influenced markedly by the sensitivity of Plasmodium falciparum to the
antimalarial drug (Sulfadoxine-Pyrimethamine) used for IPTi.
In order to interpret the results of individual IPTi trials conducted by the IPTi Consortium,
and to provide information for policy makers regarding the predicted efficacy of IPTi, it is
essential to obtain information on antimalarial drug sensitivity of Sulfadoxine-Pyrimethamine
now that the IPTi trial has been conducted. The simplest and most universally accepted
measure of testing for antimalarial drug efficacy is the "in vivo efficacy study," which
follows a standardized World Health Organization protocol.
A second reason for evaluating drug resistance as an adjunct to the IPTi trials is to
determine if the intervention increases the carriage and/or spread of drug resistant P.
falciparum parasites.
Thirdly the overall effect at the community level of selection of resistant genotypes in
IPTi-recipients is unclear.
Phase:
Phase 4
Details
Lead Sponsor:
Albert Schweitzer Hospital
Collaborator:
Bill and Melinda Gates Foundation
Treatments:
Fanasil, pyrimethamine drug combination Pyrimethamine Sulfadoxine